Oncology Learning NetworkBotensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer

Refractory microsatellite-stable metastatic colorectal cancer carries a poor prognosis, with current standard-of-care regimens delivering median overall survival of 5 to 11 months. This cross-trial comparison evaluated botensilimab plus balstilimab, a novel Fc-enhanced anti-CTLA4 and anti-PD-1 combination, against four standard-of-care regimens across SUNLIGHT, FRESCO-2, RECOURSE, and CORRECT trials.

Clinical Considerations

• Botensilimab plus balstilimab showed significantly longer OS versus FTD-TPI plus bevacizumab (HR 0.62) and outperformed fruquintinib, regorafenib, and FTD-TPI monotherapy on OS, although PFS favored FTD-TPI plus bevacizumab (HR 0.46), consistent with delayed immunotherapy response kinetics
• Patients without active liver metastases showed markedly better outcomes, with median OS of 20.9 months versus 7.4 months in those with active liver involvement, suggesting metastatic site as a potential predictive biomarker
• Immunotherapy toxicity profile differed substantially from chemotherapy regimens: lower rates of hematologic toxicity, nausea, and anemia, but higher rates of fatigue, diarrhea, and immune-mediated colitis requiring infliximab in some patients
• Critical limitation: this is a phase I versus phase III cross-trial comparison with non-randomized, heterogeneous populations; results are hypothesis-generating only, the randomized ACTIVATE-Colorectal trial is ongoing

Practice Applications

• Familiarize yourself with botensilimab plus balstilimab as an emerging option ahead of randomized phase 2 ACTIVATE-Colorectal trial results
• Assess liver metastasis status when evaluating immunotherapy candidacy in refractory MSS mCRC patients
• Monitor for immune-mediated diarrhea and colitis; early infliximab use resolved symptoms in the majority of affected patients in the phase I trial
• Evaluate patients for clinical and molecular biomarkers, including metastatic site and future PD-L1 data, as selection criteria for immunotherapy in this historically cold tumor type

More in CRC